<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Optic neuritis: Prognosis and treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Optic neuritis: Prognosis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Optic neuritis: Prognosis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Osborne, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura J Balcer, MD, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul W Brazis, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Optic neuritis is an inflammatory, demyelinating condition that causes acute, usually monocular, visual loss. It is highly associated with multiple sclerosis (MS), occurring in 50 percent of individuals at some time during the course of their illness [<a href="#rid1">1-4</a>]. Optic neuritis is the presenting feature of MS in 15 to 20 percent of patients.</p><p>The prognosis and treatment of demyelinating optic neuritis will be reviewed in this topic. The epidemiology, pathophysiology, clinical features, and diagnosis of optic neuritis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis"</a>.)</p><p>The term "optic neuritis" is sometimes applied to other inflammatory and infectious conditions affecting the optic nerve. These and other causes of optic neuropathy and the management of MS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5244.html" rel="external">"Optic neuropathies"</a> and  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'NMOSD'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognostic concerns in patients with optic neuritis are visual recovery, recurrence of optic neuritis, and risk of multiple sclerosis (MS).</p><p class="headingAnchor" id="H3"><span class="h2">Recovery of vision</span><span class="headingEndMark"> — </span>Without treatment, vision begins to improve after a few weeks [<a href="#rid5">5</a>]. Improvement can continue over many months; 90 percent have 20/40 or better vision at one year. Some patients may have a more or less favorable prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower visual acuity at the time of presentation is associated with less complete recovery; however, even those who have no light perception at presentation can recover normal vision [<a href="#rid6">6,7</a>]. In the Optic Neuritis Treatment Trial (ONTT), 64 percent of patients whose vision at presentation was no better than light perception achieved a final visual acuity of 20/40 or better [<a href="#rid8">8</a>]. Severe vision loss at one month, however, is less likely to be associated with good visual recovery [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer lesions in the optic nerve, as demonstrated on magnetic resonance imaging (MRI), particularly those extending into the optic canal, are associated with poorer visual outcome [<a href="#rid10">10,11</a>]. A number of studies have found that reduced axial diffusivity on diffusion tensor MRI (DTI) correlates with prolonged latency of visual evoked potentials and worse visual outcome on follow-up [<a href="#rid12">12-14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>African American patients have a worse prognosis for visual recovery in comparison with White Americans [<a href="#rid15">15-17</a>]. Data on 86 patients from one center found that African American patients had more severe visual loss both at presentation (worse than 20/200 in 93 versus 39 percent) and at one year (worse than 20/200 in 17 versus 5 percent) [<a href="#rid15">15</a>]. At one year, only 61 percent of African Americans had better than 20/40 acuity compared with 92 percent of White Americans. A worse visual prognosis has also been described in Black South Africans [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>While most children with optic neuritis have a good visual outcome despite a more severe visual deficit on presentation, approximately 20 percent will have persistent functional visual impairment [<a href="#rid19">19-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MS may have a somewhat less favorable prognosis than those without [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with neuromyelitis optica spectrum disorder (NMOSD), in particular those with aquaporin-4 (AQP4) autoantibodies, are at elevated risk for both recurrent optic neuritis and poor visual outcomes (visual acuity &lt;20/200) [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with optic neuritis associated with positive serum myelin oligodendrocyte glycoprotein (MOG) antibodies (MOGAD) may be at increased risk for recurrent optic neuritis but typically have better visual outcomes compared with patients with NMOSD optic neuritis [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/132021.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p>Visual recovery is typically measured by acuity. However, one study found that patients with recovery of full visual acuity after optic neuritis may have persistent deficits in tasks that require visual motion perception [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Recurrence</span><span class="headingEndMark"> — </span>In the ONTT, there was a 35 percent recurrence of optic neuritis at 10 years: 14 percent in the original eye, 12 percent in the other eye, and 9 percent in both eyes [<a href="#rid7">7</a>]. Other studies have also found high rates of recurrence [<a href="#rid29">29</a>].</p><p>Individuals with recurrent optic neuritis have a greater risk of developing MS [<a href="#rid22">22,30-33</a>]. Recurrent optic neuritis in combination with seropositivity for the AQP4 autoantibody is diagnostic of NMOSD and predicts an elevated risk of recurrence [<a href="#rid32">32,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis", section on 'Prognosis'</a>.)</p><p>Patients with recurrent optic neuritis that is not associated with MS, neuromyelitis optica (NMO), or MOG should be investigated for other causes. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Risk of multiple sclerosis</span><span class="headingEndMark"> — </span>In the ONTT, the five-year incidence of clinically definite MS was 30 percent following a first episode of idiopathic demyelinating optic neuritis [<a href="#rid35">35</a>]. The cumulative incidence increased to 40 percent at 12 years and 50 percent at 15 years [<a href="#rid30">30,36</a>]. The median time to diagnosis of MS was three years. Other series have reported similar results [<a href="#rid31">31,37,38</a>].</p><p>Demographic characteristics associated with risk of MS include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age.</strong> In many series, the risk of MS appears to be lower if the initial attack of optic neuritis occurs in childhood [<a href="#rid20">20,22</a>]. In one investigation, MS occurred in 13 percent of 94 children at 10 years and in 19 percent at 20 years [<a href="#rid22">22</a>]. However, in two other case series, the cumulative two-year risk of MS in children with optic neuritis was much higher, 36 to 45 percent [<a href="#rid24">24,39</a>].</p><p></p><p class="bulletIndent1">Among adults, patients who present with optic neuritis at an older age (greater than 35 to 40 years) may be somewhat less likely to develop MS [<a href="#rid31">31,40,41</a>]. Optic neuritis itself is relatively uncommon in individuals over 40 years. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex.</strong> Females may be somewhat more likely to develop MS after optic neuritis than males. In one prospective investigation of patients with optic neuritis followed for 15 years, MS developed in 74 percent of females and 34 percent of males [<a href="#rid42">42</a>]. A higher risk in females was also reported by the Optic Neuritis Study Group and others [<a href="#rid30">30,31,36</a>]. Others have not found that sex influences MS risk in multivariate analysis [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethnic and regional influences.</strong> In the United States, Asian Americans appear to be less likely to develop MS after optic neuritis than are White Americans.</p><p></p><p class="bulletIndent1">The lower incidence rates of MS after optic neuritis in Mexican and South American populations are consistent with the regional variation seen in MS overall [<a href="#rid43">43-45</a>]. Similarly, the reported risks are also lower in Asian countries, while in Australia and Western Europe, incidence rates are similar to those reported in the ONTT [<a href="#rid31">31,41,46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/96016.html" rel="external">"Pathogenesis and epidemiology of multiple sclerosis", section on 'Geographic factors'</a>.)</p><p></p><p>Clinical and laboratory features at the time of presentation with optic neuritis are also helpful in determining prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI abnormalities.</strong> The presence of characteristic demyelinating lesions on MRI is a strong predictor of developing MS. In the ONTT, the risk of MS after 15 years was 72 percent among those with one or more lesions on MRI versus 25 percent among those with no lesions [<a href="#rid30">30,36</a>]. The risk did not significantly differ between those with single versus multiple lesions. Other studies report similar results, including two in pediatric populations [<a href="#rid24">24,40,48,49</a>].</p><p></p><p class="bulletIndent1">In the ONTT, an abnormal brain MRI dominated other clinical and demographic risk factors, which were useful in prognosis only among those with a normal brain MRI [<a href="#rid30">30</a>]. No patient developed MS after 10 years of follow-up if they had no white matter lesions on brain MRI along with any one of the following clinical features considered atypical for optic neuritis: no pain, no light perception vision at presentation, severe disc swelling, peripapillary hemorrhage, or retinal exudates.</p><p></p><p class="bulletIndent1">MRI findings also predict future MS-related disability. In one prospective series of 106 patients with optic neuritis, the presence of baseline gadolinium-enhancing lesions and the presence and number of infratentorial and spinal cord lesions were predictive of disability among those who developed MS [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent episode of optic neuritis.</strong> Recurrent optic neuritis is more common among those destined to develop MS [<a href="#rid30">30,31,37</a>]. Patients with recurrent optic neuritis may be particularly at risk for NMOSD or MOGAD. This is particularly true for patients with a normal brain MRI and those with optic neuritis events in rapid succession. In these patients, testing the serum for AQP4 or MOG antibodies is recommended [<a href="#rid32">32,34,50-52</a>]. (See  <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">"Optic neuritis: Pathophysiology, clinical features, and diagnosis", section on 'Antibody testing'</a>.)</p><p></p><p class="bulletIndent1">By contrast, simultaneous bilateral involvement of the optic nerves at the initial presentation is associated with a lower risk of MS in most but not all studies [<a href="#rid22">22,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Funduscopic examination.</strong> The presence of papillitis, especially if it is severe, is associated with a lower risk of MS, particularly among those with normal brain MRI [<a href="#rid30">30,36</a>]. Retinal perivenous sheathing is not a common finding in optic neuritis but when present does suggest a higher risk of MS [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebrospinal fluid (CSF).</strong> Studies have had somewhat conflicting results regarding the association between abnormal CSF findings (eg, oligoclonal bands [OCB], pleocytosis, myelin basic protein, immunoglobulin G [IgG] synthesis) and subsequent risk of MS [<a href="#rid31">31,40,48,53,54</a>]. Most studies find that individuals who have OCB in the CSF at the time of the optic neuritis event are at higher risk of developing MS [<a href="#rid31">31,40</a>]. However, OCB are also associated with the presence of white matter lesions on MRI and may not represent an independent risk factor [<a href="#rid53">53-58</a>]. The combination of a normal brain MRI and absent OCB identifies individuals at very low risk of MS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human leukocyte antigen (HLA).</strong> The HLA type has been reported to affect the relationship between optic neuritis and MS [<a href="#rid59">59</a>]. One prospective study of patients with optic neuritis found a higher risk for conversion to MS among those with HLA-DR2 alleles [<a href="#rid41">41</a>]. Some investigations have corroborated this association, but others have not [<a href="#rid31">31,40,59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum antibodies.</strong> Investigators have sought a specific serum marker for MS, which remains elusive. </p><p></p><p class="bulletIndent1">Seropositivity for AQP4-specific serum antibody in patients with recurrent episodes of optic neuritis identifies patients with NMOSD, while MOG autoantibodies suggest MOGAD. (See  <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis", section on 'AQP4 autoantibody'</a> and  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'MOG autoantibody'</a>.) </p><p></p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatments for patients with optic neuritis are focused on improving vision and preventing or ameliorating the development of multiple sclerosis (MS).</p><p>Other topics discuss the treatment of MS and the treatment of neuromyelitis optica (NMO). (See  <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">"Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1686.html" rel="external">"Treatment of secondary progressive multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults", section on 'NMOSD'</a>.)</p><p class="headingAnchor" id="H791327112"><span class="h2">Acute treatment</span></p><p class="headingAnchor" id="H7"><span class="h3">Corticosteroids</span><span class="headingEndMark"> — </span>Intravenous corticosteroids are used in selected patients with optic neuritis as there is some evidence that this treatment may delay onset of MS and hasten visual recovery. Oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is generally not used.</p><p>Patients in the Optic Neuritis Treatment Trial (ONTT) were randomly assigned to either oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (1 mg/kg per day) for 14 days with a four-day taper, intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (250 mg four times per day for three days) followed by oral prednisone (1 mg/kg per day) for 11 days with a four-day taper, or oral placebo for 14 days [<a href="#rid61">61</a>]. Patients were treated within eight days of symptom onset. The primary visual outcomes were visual acuity and contrast sensitivity.</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> accelerated the recovery of visual function; however, one-year visual outcomes were similar among treatment groups [<a href="#rid61">61</a>]. A meta-analysis of three trials, including this one, that compared treatment with intravenous methylprednisolone to placebo found no benefit of treatment on visual outcomes at six months and at one year [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> also reduced the risk of conversion to MS within the first two years in comparison with either placebo or oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (7.5 versus 14.7 and 16.7 percent) [<a href="#rid63">63</a>]. Among patients with two or more white matter lesions on magnetic resonance imaging (MRI), incidence rates for MS were 16.2 versus 32.4 and 35.9 percent. At five years, however, there were no differences in the rates of MS between treatment groups [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> arm of the study was found to have a higher two-year risk of recurrent optic neuritis in either eye, when compared with intravenous steroid therapy or with placebo (27 versus 13 and 15 percent) [<a href="#rid61">61</a>]. At 10 years, the risk of recurrent optic neuritis remained higher in the oral prednisone group when compared with the intravenous-treated group (44 versus 29 percent), but there was no longer a significant difference between the oral prednisone and placebo groups [<a href="#rid7">7,30</a>].</p><p></p><p>While subsequent small randomized trials have suggested that high-dose oral corticosteroids (<a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 500 mg; <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1250 mg) might have similar efficacy to intravenous agents in regard to vision outcomes, their small size precludes definitive conclusions, and their relatively short follow-up did not address the potential risk of recurrent optic neuritis that was observed in the ONTT [<a href="#rid64">64,65</a>].</p><p>Many patients can now be treated with home intravenous infusions of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> for episodes of optic neuritis. The side effects of treatment are minimal when given for a brief time course. The most common side effects in the ONTT were mood changes, facial flushing, sleep perturbations, weight gain, and dyspepsia [<a href="#rid61">61</a>].</p><p>A decision to treat with intravenous steroids should be made after considering all potential benefits and risks, with the understanding that long-term visual outcome is not affected by this treatment [<a href="#rid66">66,67</a>]. We use intravenous corticosteroid treatment in patients with abnormal white matter lesions on their brain MRI, since this treatment may delay the onset of MS. We also use intravenous corticosteroid therapy in those patients with either severe or bilateral vision loss, as this may hasten the speed of visual recovery. In such patients, in the rare circumstance when intravenous corticosteroids are not available, we suggest the administration of high-dose oral <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (500 mg) [<a href="#rid64">64</a>]. The observed risks associated with oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> were seen in just one trial, were unexpected, and their pathologic basis is not understood. However, we do not use oral corticosteroids for treatment of optic neuritis.</p><p class="headingAnchor" id="H8"><span class="h3">Alternative acute immunomodulatory therapy</span><span class="headingEndMark"> — </span>Alternative treatments used for acute neuroimmunologic disease include intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and plasma exchange. These do not have established efficacy in the treatment of optic neuritis.</p><p>Two randomized trials studied the potential benefit of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in 55 and 68 patients with optic neuritis [<a href="#rid68">68,69</a>]. Neither study found a difference in visual outcomes at six months. MRI outcomes and the incidence of subsequent demyelinating events at six months were also similar between treatment groups [<a href="#rid69">69</a>]. Another report of IVIG treatment in 23 patients with corticosteroid refractory optic neuritis found that 78 percent achieved vision 20/30 or better, compared with 12.5 percent in a nonrandomized, matched control group [<a href="#rid70">70</a>]. The benefit appeared sustained at one year.</p><p>Ten patients with severe optic neuritis underwent plasma exchange between 11 to 73 days after presentation and after failing to respond to intravenous corticosteroid therapy [<a href="#rid71">71</a>]. Seven patients appeared to respond with improvements in visual acuity; however, improvement was not sustained in two of these.</p><p>There is some evidence now suggesting that patients with optic neuritis due to neuromyelitis optica spectrum disorder (NMOSD) could be treated early with plasma exchange (within 7 to 14 days of symptom onset). Optic neuritis due to NMOSD is associated with poor disease outcome, and some small case series have suggested earlier treatment with plasma exchange may help visual recovery in patients who do not respond to intravenous corticosteroids. However, there are as yet no prospective randomized trials demonstrating the efficacy of this plasma exchange in acute treatment of NMOSD optic neuritis [<a href="#rid72">72,73</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Disease-modifying therapy</span><span class="headingEndMark"> — </span>We offer treatment with immunomodulatory therapies, so-called disease-modifying therapy (DMT) to patients with optic neuritis and abnormal brain MRIs. Such patients are considered to have a clinically isolated syndrome suggestive of MS. If such patients can tolerate treatment, potential benefits as demonstrated by randomized clinical trials include a longer attack-free interval, reduced number of demyelinating attacks, and a delay to MS-associated disability. The management of patients with clinically isolated syndromes is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Treatment in children</span><span class="headingEndMark"> — </span>All of the clinical trials of treatment discussed above were limited to adults. No clinical trial data are available to guide the treatment of children with optic neuritis. Given their lower risk of MS, some modifications in the treatment approach seem reasonable [<a href="#rid22">22</a>].</p><p>Intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> can be considered for acute treatment for severe debilitating bilateral vision loss in hopes of hastening recovery [<a href="#rid1">1,74,75</a>]. The risk of short-term treatment is low in children. While some clinicians recommend a longer taper rate (four to eight weeks) than is used in adults because of anecdotal reports of relapses of vision loss occurring with a shorter taper in children [<a href="#rid74">74,75</a>], this practice did not appear to lead to improved relapse rates according to one retrospective cohort study [<a href="#rid76">76</a>]. As with adults, case series suggest that the final visual outcome is not altered by this treatment [<a href="#rid19">19,20,76</a>]. </p><p>The evaluation and use of chronic immunomodulatory therapy (DMT) in children who present with clinically isolated syndromes suggestive of MS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6229.html" rel="external">"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis", section on 'Clinically isolated syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/6223.html" rel="external">"Treatment and prognosis of pediatric multiple sclerosis"</a>.)</p><p class="headingAnchor" id="H168609013"><span class="h2">Investigational treatments</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9095" href="/z/d/drug information/9095.html" rel="external">Dalfampridine</a> (4-aminopyridine; fampridine), a potassium channel blocker, may improve axonal function in patients with demyelinating disease. In one randomized crossover study in 20 patients with optic neuritis of at least six months duration, five weeks of treatment with 4-aminopyridine was associated with improved measures on visual evoked potentials, and a subset analysis showed that some patients had improved visual acuity while on treatment [<a href="#rid77">77</a>]. Further studies are needed to define the role of this treatment in patients with optic neuritis. </p><p></p><p class="bulletIndent1">While <a class="drug drug_general" data-topicid="9095" href="/z/d/drug information/9095.html" rel="external">dalfampridine</a> is approved for treatment of gait impairment in MS, the appropriate clinical use has not been clearly defined in that setting. (See  <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">"Symptom management of multiple sclerosis in adults", section on 'Dalfampridine'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythropoietin has also been investigated in a phase II clinical trial of patients with acute optic neuritis [<a href="#rid78">78</a>]. Compared with placebo, active treatment was safe and associated with reduced retinal nerve fiber layer thinning on optical coherence tomography and shortened latencies on visual evoked potential at 16 weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other investigational therapies for the treatment of acute optic neuritis that are being studied in phase I/II clinical trials include <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, and anti-LINGO monoclonal antibody [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H3539147664"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">"Society guideline links: Multiple sclerosis and related disorders"</a>.)</p><p class="headingAnchor" id="H348623848"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83437.html" rel="external">"Patient education: Optic neuritis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical course and vision outcomes</strong> – Visual recovery begins within a few weeks. Most achieve 20/40 vision or better at one year. When vision is more severely affected at onset, a good prognosis is less certain. (See <a class="local">'Recovery of vision'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of multiple sclerosis </strong>–<strong> </strong>In adults, 30 percent of individuals will develop multiple sclerosis (MS) at five years. The risk is higher, 56 percent, in those with two or more typical white matter lesions on magnetic resonance imaging (MRI). Younger children may be less likely than adults to develop MS. (See <a class="local">'Risk of multiple sclerosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment</strong> – We suggest treatment with intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> for children and adults with either severe vision loss or two or more white matter lesions on MRI (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). Treatment is associated with a more rapid recovery of vision and with delayed onset of MS, but does not impact long-term visual function. (See <a class="local">'Corticosteroids'</a> above.)</p><p></p><p class="bulletIndent1">We recommend <strong>not</strong> using oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, which does not affect short- or long-term visual outcomes in acute optic neuritis and may be associated with an increased risk of recurrent optic neuritis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Corticosteroids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-modifying therapy for multiple sclerosis</strong> – Individuals with acute optic neuritis and two or more white matter lesions on brain MRI are considered to have a clinically isolated syndrome suggestive of MS. If treatment is tolerated, potential benefits as demonstrated by randomized clinical trials include a longer attack-free interval, reduced number of demyelinating attacks, and a delay to MS-associated disability.</p><p></p><p class="bulletIndent1">Specific recommendations for treatment are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1691.html" rel="external">"Management of clinically and radiologically isolated syndromes suggestive of multiple sclerosis", section on 'Management'</a>.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.</a></li><li><a class="nounderline abstract_t">Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375.</a></li><li><a class="nounderline abstract_t">Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.</a></li><li><a class="nounderline abstract_t">Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005; 139:1101.</a></li><li><a class="nounderline abstract_t">The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673.</a></li><li><a class="nounderline abstract_t">Celesia GG, Kaufman DI, Brigell M, et al. Optic neuritis: a prospective study. Neurology 1990; 40:919.</a></li><li><a class="nounderline abstract_t">Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137:77.</a></li><li><a class="nounderline abstract_t">Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol 1997; 115:1545.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Gal RL, Beck RW, et al. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007; 69:508.</a></li><li><a class="nounderline abstract_t">Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.</a></li><li><a class="nounderline abstract_t">Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251:996.</a></li><li><a class="nounderline abstract_t">Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009; 72:589.</a></li><li><a class="nounderline abstract_t">Naismith RT, Xu J, Tutlam NT, et al. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010; 74:1702.</a></li><li><a class="nounderline abstract_t">Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch Neurol 2012; 69:65.</a></li><li><a class="nounderline abstract_t">Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186.</a></li><li><a class="nounderline abstract_t">Kimbrough DJ, Sotirchos ES, Wilson JA, et al. Retinal damage and vision loss in African American multiple sclerosis patients. Ann Neurol 2015; 77:228.</a></li><li><a class="nounderline abstract_t">Moss HE, Gao W, Balcer LJ, Joslin CE. Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial. JAMA Ophthalmol 2014; 132:421.</a></li><li><a class="nounderline abstract_t">Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye (Lond) 2001; 15:469.</a></li><li><a class="nounderline abstract_t">Brady KM, Brar AS, Lee AG, et al. Optic neuritis in children: clinical features and visual outcome. J AAPOS 1999; 3:98.</a></li><li><a class="nounderline abstract_t">Kriss A, Francis DA, Cuendet F, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988; 51:1253.</a></li><li><a class="nounderline abstract_t">KENNEDY C, CARROLL FD. Optic neuritis in children. Arch Ophthalmol 1960; 63:747.</a></li><li><a class="nounderline abstract_t">Lucchinetti CF, Kiers L, O'Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49:1413.</a></li><li><a class="nounderline abstract_t">Riikonen R, Donner M, Erkkilä H. Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol 1988; 30:349.</a></li><li><a class="nounderline abstract_t">Absoud M, Cummins C, Desai N, et al. Childhood optic neuritis clinical features and outcome. Arch Dis Child 2011; 96:860.</a></li><li><a class="nounderline abstract_t">Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008; 115:1079.</a></li><li><a class="nounderline abstract_t">Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015; 72:187.</a></li><li><a class="nounderline abstract_t">Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol 2020; 11:540156.</a></li><li><a class="nounderline abstract_t">Raz N, Dotan S, Benoliel T, et al. Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence. Neurology 2011; 76:2103.</a></li><li><a class="nounderline abstract_t">Deschamps R, Gueguen A, Lecler A, et al. Acute idiopathic optic neuritis: not always benign. Eur J Neurol 2018; 25:1378.</a></li><li><a class="nounderline abstract_t">Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121:944.</a></li><li><a class="nounderline abstract_t">Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 2005; 252:396.</a></li><li><a class="nounderline abstract_t">Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197.</a></li><li><a class="nounderline abstract_t">Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344.</a></li><li><a class="nounderline abstract_t">Takagi M, Tanaka K, Suzuki T, et al. Anti-aquaporin-4 antibody-positive optic neuritis. Acta Ophthalmol 2009; 87:562.</a></li><li><a class="nounderline abstract_t">Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997; 49:1404.</a></li><li><a class="nounderline abstract_t">Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65:727.</a></li><li><a class="nounderline abstract_t">Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45:244.</a></li><li><a class="nounderline abstract_t">Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. Neurology 2009; 72:542.</a></li><li><a class="nounderline abstract_t">Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67:258.</a></li><li><a class="nounderline abstract_t">Jin YP, de Pedro-Cuesta J, Huang YH, Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003; 9:135.</a></li><li><a class="nounderline abstract_t">Hely MA, McManis PG, Doran TJ, et al. Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry 1986; 49:1125.</a></li><li><a class="nounderline abstract_t">Rizzo JF 3rd, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988; 38:185.</a></li><li><a class="nounderline abstract_t">Corona-Vazquez T, Ruiz-Sandoval J, Arriada-Mendicoa N. Optic neuritis progressing to multiple sclerosis. Acta Neurol Scand 1997; 95:85.</a></li><li><a class="nounderline abstract_t">Alvarez G, Cárdenas M. Multiple sclerosis following optic neuritis in Chile. J Neurol Neurosurg Psychiatry 1989; 52:115.</a></li><li><a class="nounderline abstract_t">Lana-Peixoto MA, Lana-Peixoto MI. The risk of multiple sclerosis developing in patients with isolated idiopathic optic neuritis in Brazil. Arq Neuropsiquiatr 1991; 49:377.</a></li><li><a class="nounderline abstract_t">Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol 2001; 29:312.</a></li><li><a class="nounderline abstract_t">Wakakura M, Minei-Higa R, Oono S, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43:127.</a></li><li><a class="nounderline abstract_t">Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997; 41:392.</a></li><li><a class="nounderline abstract_t">Alper G, Wang L. Demyelinating optic neuritis in children. J Child Neurol 2009; 24:45.</a></li><li><a class="nounderline abstract_t">Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004; 61:1401.</a></li><li><a class="nounderline abstract_t">Padungkiatsagul T, Chen JJ, Jindahra P, et al. Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race. Am J Ophthalmol 2020; 219:332.</a></li><li><a class="nounderline abstract_t">Tajfirouz DA, Bhatti MT, Chen JJ. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. Curr Neurol Neurosci Rep 2019; 19:100.</a></li><li><a class="nounderline abstract_t">Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996; 46:368.</a></li><li><a class="nounderline abstract_t">Cole SR, Beck RW, Moke PS, et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51:885.</a></li><li><a class="nounderline abstract_t">Söderström M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50:708.</a></li><li><a class="nounderline abstract_t">Frederiksen JL, Madsen HO, Ryder LP, et al. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 1997; 54:76.</a></li><li><a class="nounderline abstract_t">Frederiksen JL, Larsson HB, Olesen J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1992; 86:317.</a></li><li><a class="nounderline abstract_t">Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139.</a></li><li><a class="nounderline abstract_t">Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987; 50:758.</a></li><li><a class="nounderline abstract_t">Kheradvar A, Tabassi AR, Nikbin B, et al. Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study. Mult Scler 2004; 10:526.</a></li><li><a class="nounderline abstract_t">Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581.</a></li><li><a class="nounderline abstract_t">Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2012; :CD001430.</a></li><li><a class="nounderline abstract_t">Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329:1764.</a></li><li><a class="nounderline abstract_t">Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52:1479.</a></li><li><a class="nounderline abstract_t">Morrow SA, Fraser JA, Day C, et al. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. JAMA Neurol 2018; 75:690.</a></li><li><a class="nounderline abstract_t">Vedula SS, Brodney-Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2007; :CD001430.</a></li><li><a class="nounderline abstract_t">Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2039.</a></li><li><a class="nounderline abstract_t">Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514.</a></li><li><a class="nounderline abstract_t">Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804.</a></li><li><a class="nounderline abstract_t">Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15:1163.</a></li><li><a class="nounderline abstract_t">Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63:1081.</a></li><li><a class="nounderline abstract_t">Horton L, Bennett JL. Acute Management of Optic Neuritis: An Evolving Paradigm. J Neuroophthalmol 2018; 38:358.</a></li><li><a class="nounderline abstract_t">Han M, Chen Y, Nong L, et al. Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020; 99:e21067.</a></li><li><a class="nounderline abstract_t">Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18:174.</a></li><li><a class="nounderline abstract_t">Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. Ophthalmology 1990; 97:339.</a></li><li><a class="nounderline abstract_t">Jayakody H, Bonthius DJ, Longmuir R, Joshi C. Pediatric optic neuritis: does a prolonged course of steroids reduce relapses? A preliminary study. Pediatr Neurol 2014; 51:721.</a></li><li><a class="nounderline abstract_t">Horton L, Conger A, Conger D, et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology 2013; 80:1862.</a></li><li><a class="nounderline abstract_t">Sühs KW, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72:199.</a></li><li><a class="nounderline abstract_t">Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014; 13:83.</a></li></ol></div><div id="topicVersionRevision">Topic 5252 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554529" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice. Optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441840" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute demyelinating optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15664543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The neuro-ophthalmology of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953446" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evolving management of optic neuritis and multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1841573" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2345615" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Optic neuritis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700647" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9400788" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679669" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208717" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316805" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073948" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498438" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Radial diffusivity in remote optic neuritis discriminates visual outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911658" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482360" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Optic neuritis in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25382184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Retinal damage and vision loss in African American multiple sclerosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24557028" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the Optic Neuritis Treatment Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11767021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Optic neuritis in an urban black African community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221803" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Optic neuritis in children: clinical features and visual outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3225583" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recovery after optic neuritis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14408507" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Optic neuritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371931" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk factors for developing multiple sclerosis after childhood optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3402675" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554767" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Childhood optic neuritis clinical features and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976727" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25506781" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptorα1 subunit in patients with isolated optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33132999" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670440" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30004610" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute idiopathic optic neuritis: not always benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860795" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778816" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434643" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : NMO-IgG predicts the outcome of recurrent optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094334" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19021599" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-aquaporin-4 antibody-positive optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371930" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541792" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854520" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Optic neuritis: a population-based study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204264" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Early MRI in optic neuritis: the risk for disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864818" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The clinical features, MRI findings, and outcome of optic neuritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12708808" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predicting multiple sclerosis at optic neuritis onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3783173" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acute optic neuritis: a prospective study of risk factors for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3340278" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059726" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Optic neuritis progressing to multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2709019" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multiple sclerosis following optic neuritis in Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1842186" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The risk of multiple sclerosis developing in patients with isolated idiopathic optic neuritis in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720158" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The presentation, aetiology, management and outcome of optic neuritis in an Asian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10340795" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9066361" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936195" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Demyelinating optic neuritis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364686" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The natural history of recurrent optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32681910" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31773369" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614496" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9748050" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521261" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006417" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414254" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853586" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3497228" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471368" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734247" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513900" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Corticosteroids for treating optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232485" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227638" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507942" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253459" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Corticosteroids for treating optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10851360" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11402108" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753413" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727675" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452303" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Plasma exchange for severe optic neuritis: treatment of 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30106803" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Acute Management of Optic Neuritis: An Evolving Paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32664124" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15513003" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Optic neuritis in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2336272" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bilateral postinfectious optic neuritis and intravenous steroid therapy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25152962" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pediatric optic neuritis: does a prolonged course of steroids reduce relapses? A preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23616154" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926853" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24331795" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Optic neuritis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
